An Open-Label Extension Study of Post-Transplant Maintenance Midostaurin (PKC412) in Elderly Patients (Age ≥ 60 Years) With FLT3-ITD/TKD Mutated AML Who Previously Received Midostaurin and Decitabine as Part of Study HEMAML0022 / CPKC412AUS27T
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Midostaurin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 May 2018 Planned End Date changed from 1 May 2021 to 1 Apr 2018.
- 01 May 2018 Planned primary completion date changed from 1 May 2020 to 1 Apr 2018.
- 01 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.